Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:786870.
doi: 10.1155/2012/786870. Epub 2012 Feb 28.

Anti-VEGF Treatment Strategies for Wet AMD

Jaclyn L Kovach  1 , Stephen G Schwartz, Harry W Flynn Jr, Ingrid U Scott
Affiliations

Anti-VEGF Treatment Strategies for Wet AMD

Jaclyn L Kovach et al. J Ophthalmol. 2012.

Abstract

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ranibizumab is a recombinant humanized monoclonal antibody fragment. Bevacizumab is a recombinant humanized IgG antibody. Both bind to and inhibit all biologically active forms of VEGF-A and are derived from the same mouse monoclonal antibody. Ranibizumab has been genetically engineered to bind with higher affinity than bevacizumab (see [8]).
Figure 2
Figure 2
(a) A binding domain of VEGFR1 and VEGFR2 are fused to create 2 dual-domain arms for each VEGF Trap-Eye molecule. (b) The Fc portion of the IgG is fused to the two dual-domain arms to create the VEGF Trap-Eye molecule (see [9]).
See this image and copyright information in PMC

References

    1. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological Reports. 2006;58(3):353–363. - PubMed
    1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews. 2004;25(4):581–611. - PubMed
    1. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116(10):S1–S7. - PubMed
    1. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of Ophthalmology. 2002;120(3):338–346. - PubMed
    1. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Archives of Ophthalmology. 2005;123(4):509–516. - PubMed